These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26423990)

  • 1. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.
    Phillips AN; Cambiano V; Miners A; Revill P; Pillay D; Lundgren JD; Bennett D; Raizes E; Nakagawa F; De Luca A; Vitoria M; Barcarolo J; Perriens J; Jordan MR; Bertagnolio S
    Lancet HIV; 2014 Nov; 1(2):e85-93. PubMed ID: 26423990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
    Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S;
    Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings.
    Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA;
    AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
    Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
    Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
    Gupta RK; Gregson J; Parkin N; Haile-Selassie H; Tanuri A; Andrade Forero L; Kaleebu P; Watera C; Aghokeng A; Mutenda N; Dzangare J; Hone S; Hang ZZ; Garcia J; Garcia Z; Marchorro P; Beteta E; Giron A; Hamers R; Inzaule S; Frenkel LM; Chung MH; de Oliveira T; Pillay D; Naidoo K; Kharsany A; Kugathasan R; Cutino T; Hunt G; Avila Rios S; Doherty M; Jordan MR; Bertagnolio S
    Lancet Infect Dis; 2018 Mar; 18(3):346-355. PubMed ID: 29198909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.
    ; Babiker A; Castro nee Green H; Compagnucci A; Fiscus S; Giaquinto C; Gibb DM; Harper L; Harrison L; Hughes M; McKinney R; Melvin A; Mofenson L; Saidi Y; Smith ME; Tudor-Williams G; Walker AS
    Lancet Infect Dis; 2011 Apr; 11(4):273-83. PubMed ID: 21288774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
    Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
    J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Impact and Cost-effectiveness of Genotype Testing at Human Immunodeficiency Virus Diagnosis in the United States.
    Hyle EP; Scott JA; Sax PE; Millham LRI; Dugdale CM; Weinstein MC; Freedberg KA; Walensky RP
    Clin Infect Dis; 2020 Mar; 70(7):1353-1363. PubMed ID: 31055599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of pre-ART HIV drug resistance testing in Kenyan women.
    Duarte HA; Babigumira JB; Enns EA; Stauffer DC; Shafer RW; Beck IA; Garrison LP; Chung MH; Frenkel LM; Bendavid E
    EClinicalMedicine; 2020 May; 22():100355. PubMed ID: 32490370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.
    Gupta RK; Jordan MR; Sultan BJ; Hill A; Davis DH; Gregson J; Sawyer AW; Hamers RL; Ndembi N; Pillay D; Bertagnolio S
    Lancet; 2012 Oct; 380(9849):1250-8. PubMed ID: 22828485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicted levels of HIV drug resistance: potential impact of expanding diagnosis, retention, and eligibility criteria for antiretroviral therapy initiation.
    Cambiano V; Bertagnolio S; Jordan MR; Pillay D; Perriëns JH; Venter F; Lundgren J; Phillips A
    AIDS; 2014 Jan; 28 Suppl 1():S15-23. PubMed ID: 24468943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study.
    Hamers RL; Wallis CL; Kityo C; Siwale M; Mandaliya K; Conradie F; Botes ME; Wellington M; Osibogun A; Sigaloff KC; Nankya I; Schuurman R; Wit FW; Stevens WS; van Vugt M; de Wit TF;
    Lancet Infect Dis; 2011 Oct; 11(10):750-9. PubMed ID: 21802367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and characteristics of HIV drug resistance among antiretroviral treatment (ART) experienced adolescents and young adults living with HIV in Ndola, Zambia.
    Miti S; Handema R; Mulenga L; Mwansa JK; Abrams E; Frimpong C; Burke VM; Zulu M; Siwingwa M; Mwakazanga D; Kalibala S; Denison JA
    PLoS One; 2020; 15(8):e0236156. PubMed ID: 32804970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.
    Phillips A; Cambiano V; Nakagawa F; Mabugu T; Miners A; Ford D; Pillay D; De Luca A; Lundgren J; Revill P
    PLoS One; 2014; 9(10):e109148. PubMed ID: 25290340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
    Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
    Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.